Post-marketing Observational Study in Subjects With Rheumatoid Arthritis

Study Identifier
M03-634
CT.gov Identifier
NCT00234884
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Rheumatoid Arthritis
    • Study Drug
  • adalimumab
    • Phase
    PMOS
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    - Participants with ongoing adalimumab treatment who completed at least Month 3 (Visit 5) of NCT00448383 (Study M02-497) and who had subsequently been prescribed adalimumab according to the Summary of Product Characteristics (SmPC). - Participants must have been willing to consent to data being collected and provided to Abbott.
    Exclusion Criteria:
    · Participants with contraindications according to the SmPC.

    Protocol Summary

    The purpose of this observational study was to observe and assess the long term use, safety,

    and effectiveness of adalimumab in a normal clinical setting.

    Study Locations

    Location
    Status
    Location
    Site Ref # / Investigator 5606
    Camperdown, New South Wales, Australia, 2050
    Status
    Not applicable
    Location
    Site Ref # / Investigator 49504
    New Lambton, New South Wales, Australia, 2305
    Status
    Not applicable
    Location
    Site Ref # / Investigator 49508
    Brisbane, Queensland, Australia, 4102
    Status
    Not applicable
    Location
    Site Ref # / Investigator 49505
    Woodville, South Australia, Australia, 5011
    Status
    Not applicable
    Location
    Site Ref # / Investigator 49503
    West Heidelberg, Victoria, Australia, 3081
    Status
    Not applicable
    Location
    Site Ref # / Investigator 49502
    Cairns, Australia, 4870
    Status
    Not applicable
    Showing {first} - {last} of {total} Results